A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of KX-826 for Topical Use in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Pyrilutamide (Primary)
- Indications Alopecia
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Kintor Pharmaceuticals
- 01 Apr 2024 Planned primary completion date changed from 11 Jan 2024 to 31 May 2024.
- 11 May 2023 According to a Kintor Pharma media release, topline data is expected in the fourth quarter of 2023.
- 28 Mar 2023 Status changed from recruiting to active, no longer recruiting as per Kintor Pharma media release